Associations - BRAF V600E

BRAF V600E BRAF V600E	Thyroid Gland Papillary Carcinoma Thyroid Gland Papillary Carcinoma	trametinib + dabrafenib + AZD1775 Sensitive: D – Preclinical Cancers (Basel) - 2 weeks
BRAF V600E BRAF V600E	Colorectal Cancer CRC	cetuximab + encorafenib + binimetinib Sensitive: A1 - Approval
BRAF V600E BRAF V600E	Colorectal Cancer CRC	cetuximab + encorafenib Sensitive: A1 - Approval
BRAF V600E BRAF V600E	Melanoma Melanoma	dabrafenib Sensitive: A1 - Approval
BRAF V600E BRAF V600E	Non Small Cell Lung Cancer NSCLC	trametinib + dabrafenib Sensitive: A1 - Approval
BRAF V600E BRAF V600E	Thyroid Gland Anaplastic Carcinoma Thyroid Gland Anaplastic Carcinoma	trametinib + dabrafenib Sensitive: A1 - Approval
BRAF V600E BRAF V600E	Thyroid Gland Anaplastic Carcinoma Thyroid Gland Anaplastic Carcinoma	dabrafenib Sensitive: A1 - Approval
BRAF V600E BRAF V600E	Melanoma Melanoma	trametinib + dabrafenib Sensitive: A1 - Approval
BRAF V600E BRAF V600E	Melanoma Melanoma	vemurafenib + cobimetinib Sensitive: A1 - Approval
BRAF V600E BRAF V600E	Melanoma Melanoma	vemurafenib Sensitive: A1 - Approval
BRAF V600E BRAF V600E	Melanoma Melanoma	trametinib Sensitive: A1 - Approval
BRAF V600E BRAF V600E	Melanoma Melanoma	encorafenib + binimetinib Sensitive: A1 - Approval
BRAF V600E BRAF V600E	Non Small Cell Lung Cancer NSCLC	vemurafenib Sensitive: A2 - Guideline
BRAF V600E BRAF V600E	Glioblastoma GBM	trametinib + dabrafenib Sensitive: A2 - Guideline
BRAF V600E BRAF V600E	Ganglioglioma Ganglioglioma	trametinib + dabrafenib Sensitive: A2 - Guideline
BRAF V600E BRAF V600E	Ganglioglioma Ganglioglioma	vemurafenib + cobimetinib Sensitive: A2 - Guideline
BRAF V600E BRAF V600E	Ganglioglioma Ganglioglioma	vemurafenib Sensitive: A2 - Guideline
BRAF V600E BRAF V600E	Cutaneous Melanoma Cutaneous Melanoma	trametinib + dabrafenib Sensitive: A2 - Guideline
BRAF V600E BRAF V600E	Biliary Tract Cancer Biliary Tract Cancer	trametinib + dabrafenib Sensitive: A2 - Guideline
BRAF V600E BRAF V600E	Astrocytoma Astrocytoma	trametinib + dabrafenib Sensitive: A2 - Guideline
BRAF V600E BRAF V600E	Astrocytoma Astrocytoma	vemurafenib + cobimetinib Sensitive: A2 - Guideline
BRAF V600E BRAF V600E	Glioma Glioma	selumetinib Sensitive: A2 - Guideline
BRAF V600E BRAF V600E	Astrocytoma Astrocytoma	cobimetinib Sensitive: A2 - Guideline
BRAF V600E BRAF V600E	Astrocytoma Astrocytoma	vemurafenib Sensitive: A2 - Guideline
BRAF V600E BRAF V600E	Astrocytoma Astrocytoma	trametinib Sensitive: A2 - Guideline
BRAF V600E BRAF V600E	Astrocytoma Astrocytoma	dabrafenib Sensitive: A2 - Guideline
BRAF V600E BRAF V600E	Ganglioglioma Ganglioglioma	cobimetinib Sensitive: A2 - Guideline
BRAF V600E BRAF V600E	Ganglioglioma Ganglioglioma	trametinib Sensitive: A2 - Guideline
BRAF V600E BRAF V600E	Ganglioglioma Ganglioglioma	dabrafenib Sensitive: A2 - Guideline
BRAF V600E BRAF V600E	Cutaneous Melanoma Cutaneous Melanoma	pembrolizumab Sensitive: A2 - Guideline
BRAF V600E BRAF V600E	Cutaneous Melanoma Cutaneous Melanoma	nivolumab Sensitive: A2 - Guideline
BRAF V600E BRAF V600E	Colorectal Cancer CRC	panitumumab + encorafenib Sensitive: A2 - Guideline
BRAF V600E BRAF V600E	Colorectal Cancer CRC	trametinib + dabrafenib + panitumumab Sensitive: A2 - Guideline
BRAF V600E BRAF V600E	Colorectal Cancer CRC	cetuximab + trametinib + dabrafenib Sensitive: A2 - Guideline
BRAF V600E BRAF V600E	Cutaneous Melanoma Cutaneous Melanoma	encorafenib + binimetinib Sensitive: A2 - Guideline
BRAF V600E BRAF V600E	Cutaneous Melanoma Cutaneous Melanoma	vemurafenib + cobimetinib Sensitive: A2 - Guideline
BRAF V600E BRAF V600E	Cutaneous Melanoma Cutaneous Melanoma	dabrafenib Sensitive: A2 - Guideline
BRAF V600E BRAF V600E	Cutaneous Melanoma Cutaneous Melanoma	vemurafenib Sensitive: A2 - Guideline
BRAF V600E BRAF V600E	Biliary Tract Cancer Biliary Tract Cancer	pembrolizumab + lenvatinib Sensitive: A2 - Guideline
BRAF V600E BRAF V600E	Glioblastoma GBM	vemurafenib + cobimetinib Sensitive: A2 - Guideline
BRAF V600E BRAF V600E	Melanoma Melanoma	nivolumab + ipilimumab Sensitive: B - Late Trials
BRAF V600E BRAF V600E	Melanoma Melanoma	pembrolizumab Sensitive: B - Late Trials
BRAF V600E BRAF V600E	Colorectal Cancer CRC	trifluridine/tipiracil Sensitive: B - Late Trials
BRAF V600E BRAF V600E	Colorectal Cancer CRC	cetuximab Resistant: B - Late Trials
BRAF V600E BRAF V600E	Melanoma Melanoma	encorafenib Sensitive: B - Late Trials
BRAF V600E BRAF V600E	Colorectal Cancer CRC	encorafenib Sensitive: B - Late Trials
BRAF V600E BRAF V600E	Colorectal Cancer CRC	encorafenib + binimetinib Sensitive: B - Late Trials
BRAF V600E BRAF V600E	Melanoma Melanoma	nivolumab Sensitive: B - Late Trials
BRAF V600E BRAF V600E	Colorectal Cancer CRC	bevacizumab Resistant: B - Late Trials
BRAF V600E BRAF V600E	Non Small Cell Lung Cancer NSCLC	dabrafenib Sensitive: C1 - Off-label
BRAF V600E BRAF V600E	Neuroendocrine Tumor Neuroendocrine Tumor	trametinib + dabrafenib Sensitive: C1 - Off-label
BRAF V600E BRAF V600E	Neurofibrosarcoma Neurofibrosarcoma	vemurafenib Sensitive: C1 - Off-label
BRAF V600E BRAF V600E	Ovarian Serous Adenocarcinoma Ovarian Serous Adenocarcinoma	encorafenib + binimetinib Sensitive: C1 - Off-label
BRAF V600E BRAF V600E	Glioblastoma GBM	vemurafenib Sensitive: C1 - Off-label
BRAF V600E BRAF V600E	Pancreatic Cancer Pancreatic Cancer	encorafenib + binimetinib Sensitive: C1 - Off-label
BRAF V600E BRAF V600E	Solid Tumor Solid Tumor	trametinib + dabrafenib Sensitive: C1 - Off-label
BRAF V600E BRAF V600E	Cholangiocarcinoma Cholangiocarcinoma	trametinib + dabrafenib Sensitive: C1 - Off-label
BRAF V600E BRAF V600E	Glioblastoma GBM	dabrafenib Sensitive: C1 - Off-label
BRAF V600E BRAF V600E	Lung Adenocarcinoma LUAD	trametinib + dabrafenib Sensitive: C1 - Off-label
BRAF V600E BRAF V600E	Multiple Myeloma Multiple Myeloma	vemurafenib Sensitive: C1 - Off-label
BRAF V600E BRAF V600E	Colorectal Cancer CRC	trametinib + dabrafenib Sensitive: C1 - Off-label
BRAF V600E BRAF V600E	Colorectal Cancer CRC	vemurafenib Sensitive: C1 - Off-label
BRAF V600E BRAF V600E	Ovarian Cancer Ovarian Cancer	vemurafenib Sensitive: C1 - Off-label
BRAF V600E BRAF V600E	Ovarian Cancer Ovarian Cancer	trametinib + dabrafenib Sensitive: C1 - Off-label
BRAF V600E BRAF V600E	Head and Neck Cancer Head and Neck Cancer	vemurafenib Sensitive: C1 - Off-label
BRAF V600E BRAF V600E	Colorectal Cancer CRC	dabrafenib Sensitive: C1 - Off-label
BRAF V600E BRAF V600E	Cutaneous Melanoma Cutaneous Melanoma	trametinib Sensitive: C1 - Off-label
BRAF V600E BRAF V600E	Thyroid Gland Carcinoma Thyroid Gland Carcinoma	dabrafenib Sensitive: C1 - Off-label
BRAF V600E BRAF V600E	Thyroid Gland Carcinoma Thyroid Gland Carcinoma	trametinib Sensitive: C1 - Off-label
BRAF V600E BRAF V600E	Thyroid Gland Papillary Carcinoma Thyroid Gland Papillary Carcinoma	trametinib + dabrafenib Sensitive: C1 - Off-label
BRAF V600E BRAF V600E	Solid Tumor Solid Tumor	encorafenib + binimetinib Sensitive: C1 - Off-label
BRAF V600E BRAF V600E	Thyroid Gland Papillary Carcinoma Thyroid Gland Papillary Carcinoma	vemurafenib Sensitive: C1 - Off-label
BRAF V600E BRAF V600E	Thyroid Gland Anaplastic Carcinoma Thyroid Gland Anaplastic Carcinoma	vemurafenib Resistant: C1 - Off-label
BRAF V600E BRAF V600E	Thyroid Gland Carcinoma Thyroid Gland Carcinoma	vemurafenib Sensitive: C1 - Off-label
BRAF V600E BRAF V600E	Pancreatic Cancer Pancreatic Cancer	vemurafenib Sensitive: C1 - Off-label
BRAF V600E BRAF V600E	Ocular Melanoma Ocular Melanoma	trametinib + dabrafenib Sensitive: C1 - Off-label
BRAF V600E BRAF V600E	Non Small Cell Lung Cancer NSCLC	trametinib Sensitive: C1 - Off-label
BRAF V600E BRAF V600E	Gastric Cancer Gastric Cancer	vemurafenib Sensitive: C1 - Off-label
BRAF V600E BRAF V600E	Biliary Tract Cancer Biliary Tract Cancer	trametinib Sensitive: C1 - Off-label
BRAF V600E BRAF V600E	Multiple Myeloma Multiple Myeloma	vemurafenib + cobimetinib Sensitive: C1 - Off-label
BRAF V600E BRAF V600E	Glioma Glioma	trametinib + dabrafenib Sensitive: C1 - Off-label
BRAF V600E BRAF V600E	Non Small Cell Lung Cancer NSCLC	durvalumab Sensitive: C2 – Inclusion Criteria
BRAF V600E BRAF V600E	Astrocytoma Astrocytoma	selumetinib Sensitive: C2 – Inclusion Criteria
BRAF V600E BRAF V600E	Melanoma Melanoma	pembrolizumab + trametinib + dabrafenib Sensitive: C2 – Inclusion Criteria
BRAF V600E BRAF V600E	Colorectal Cancer CRC	cetuximab + vemurafenib Sensitive: C2 – Inclusion Criteria
BRAF V600E BRAF V600E	Colorectal Cancer CRC	vemurafenib + panitumumab Sensitive: C2 – Inclusion Criteria
BRAF V600E BRAF V600E	Hairy Cell Leukemia Hairy Cell Leukemia	dabrafenib Sensitive: C2 – Inclusion Criteria
BRAF V600E BRAF V600E	Melanoma Melanoma	vemurafenib + atezolizumab + cobimetinib Sensitive: C2 – Inclusion Criteria
BRAF V600E BRAF V600E	Solid Tumor Solid Tumor	trametinib + dabrafenib + AT13387 Sensitive: C2 – Inclusion Criteria
BRAF V600E BRAF V600E	Colorectal Cancer CRC	trametinib + dabrafenib + PDR001 Sensitive: C2 – Inclusion Criteria
BRAF V600E BRAF V600E	Colorectal Cancer CRC	cetuximab + vemurafenib Sensitive: C2 – Inclusion Criteria
BRAF V600E BRAF V600E	Melanoma Melanoma	ipilimumab Sensitive: C2 – Inclusion Criteria
BRAF V600E BRAF V600E	Hairy Cell Leukemia Hairy Cell Leukemia	vemurafenib Sensitive: C2 – Inclusion Criteria